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Abstract
With the unavoidable progress of genomics technologies, “one size fits all” strategy has 
switched to individual-specific treatment approaches. Hence pharmacogenomics-based 
personalized cancer medicine has emerged. Promising treatment option immunotherapy 
includes either “take the brakes off immune system (i.e., checkpoint blockade therapy) or 
the use of immune cells expanded in an in vitro tumor-free environment’’. Both options 
have been varied and included unpredictable results. Combination of cancer immuno-
therapy and pharmacogenomics applications may contribute to solve the complexity of 
outcome prediction and variations between individuals receiving the same immunother-
apeutic treatment. To enhance the tumor immunity and determine cancer patients who 
response to immunotherapy, classification based on gene polymorphisms in key immu-
noregulatory molecules including antigen-presenting molecules, immunoglobulins and 
their receptors, cytokine/chemokines and their receptors, adhesion and costimulatory 
molecules, toll-like receptors, and intracellular signaling molecules plays a vital role in 
redirecting or modulating the function of immune cells. Therefore, polymorphisms in 
immunoregulatory molecules and their impact on immunotherapeutic outcome should 
be considered in cancer management.
Keywords: cancer, immunopharmacogenomics, personalized immunotherapy, 
polymorphisms
1. Introduction
The host immune system has a crucial role on the pathogenesis of many diseases, including 
cancer. Tumorigenesis depends not only on cellular biology but also on immune responses. 
The tumor development and progression are associated with the interaction between the 
immune system and malignant cells. The effect of immune responses has been counted on 
for both cancer immunotherapies and a broad range of cytotoxic agents as well as molecular 
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targeted drugs. With the accumulation of information about the immune responses in tumor 
immune surveillance, the fame of cancer immunotherapy is increasing. Some cancer immu-
notherapies, such as monoclonal antibodies, cytokines, cancer vaccines, and cell-based thera-
pies, have been developed and incorporated into clinical practice for the activation of the host 
immune response to eliminate cancer cells [1, 2].
2. Importance of personalized cancer therapy on immunotherapy
With characterization of alterations on immunity-related molecules through deep sequenc-
ing tools in the genomic era, immunotherapies are revolutionizing cancer treatment. Natural 
variations in nucleic acid sequence named as gene polymorphisms exist in general population 
with a high frequency and include no side effect for the people. Single nucleotide polymor-
phisms (SNPs) are the most common polymorphism in population [3]. SNPs can be also rec-
ognized as biological markers to identify genes that are associated with diseases. It has been 
displayed that some SNPs have effects on individual’s response to some drugs. Therefore 
research groups are focused on the investigation of how SNPs in the human genome correlate 
with drug response to get more successful therapy regimes in personalized medicine era [4]. 
At this point, immunopharmacogenomics that incorporates immunogenomics and pharma-
cogenomics aims to improve a better approach for how the immune system impacts to the 
immunotherapy response.
2.1. PD-1/PD-L1 polymorphisms
The blockade of immune checkpoints modulating immune responses has recently been 
emerged as an immune therapy against cancer. Different immune checkpoint molecules such 
as programmed cell death 1 receptor (PD-1), an immune checkpoint receptor on immune 
cells (especially on T lymphocytes); and programmed death-1 ligand-1 (PD-L1) on tumor 
cells or tumor-infiltrating immune cells, have been associated with tumor immune evasion 
[5]. Interaction of PD-1 with PD-L1 starts antitumor immune response suppression; therefore 
blockade of PD-1/PD-L1 binding has been recently applied for antitumor immune therapy [6]. 
PD-1 is expressed on some immune cells, including T cells, natural killer T (NKT) cells, mature 
CD4+ and CD8+ T cells, some dendritic cells, B cells, lymph node, and bone marrow cells [4]. 
PD-1 is commonly expressed immunoinhibitory receptor that belongs to CD28/B7 family, and 
it is expressed on some immune cells, including T cells, natural killer T (NKT) cells, mature 
CD4+ and CD8+ T cells, some dendritic cells, B cells, lymph node, and bone marrow cells. 
PD-1 has two opposite roles such as downregulation of ineffective immune responses and 
expansion of malignant cells by preventing of protective antitumor immune responses [7]. 
PD-1 has function on the inhibition of T-cell activation, production, and survival [4]. PD-L1, 
ligand of PD-1, is a member of the B7 family of immune-regulatory ligands. It is expressed on 
functioning active T cells, B cells, dendritic cells, and macrophages (antigen-presenting cells) 
and activates various tissue groups by inflammatory cytokines [7]. PD-L1 has two different 
forms as membrane bound and soluble form. Both of these forms have been found on CD28/
B27 family such as CTLA-4, CD28, and B7-H4 [8].
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PD-L1 has role on the negative regulation of immunological response. PD-L1 overexpression 
can prevent to form antitumor immune responses against cancer cells; hence increased expres-
sion of PD-L1 on tumor cells may be predictive for a blockade of the PD-L1/PD-1 binding [9]. 
Some studies have shown that PD-L1 is also expressed on many types of cancer cells (including 
melanoma, lung cancer), and it has been reported that expression of PD-L1 ligands by cancer 
cells results in the evasion of the immune system. They stop the production of tumor-specific 
T cells by propagation of inhibitory signals which cause damaged antitumor immunity [7, 10]. 
Based on their function on antitumor immune response suppression, PD-1 and PD-L1 can be 
considered as powerful biomarkers for new tumor formation or progression of cancer. In lit-
erature some studies are focused on their role on genetic susceptibility, and some of them are 
focused on their prognostic or predictive significance. In literature some polymorphisms on 
PD-1 which is encoded by PDCD-1 gene (Gene bank ID: 5153) on chromosome 2q37 location 
are associated with tumor susceptibility. PD-1.1 polymorphism (dbSNP reference cluster ID 
rs36084323, c.-606G > A), located in the promoter region, has been accepted as a risk factor for 
non-small cell lung cancer and breast cancer [11, 12]. PD-1.3 (rs11568821, c.627 + 189G > C,) 
located in intron 4 has been associated with colon, thyroid, and breast cancer [13–15]. PD-1.5 
(rs2227981, c.804 T > C), located in exon 5, is associated with increased cancer risks in non-
small cell lung, cervical, colon, and ovarian cancer [4, 16]. A recent study showed that PD-1.9 
(rs2227982, c.644C > T), located in exon 5, has significance on the gastric cancers [17]. PD-L1 gene 
(Gene bank ID: 29126) polymorphisms (rs2890658, c.683-369C > A, and rs10815225, c.-114C > A) 
might serve as risk markers for esophageal squamous cell carcinoma and gastric cancer [18, 
19]. Blockade of PD-1/PD-L1 pathway with specific anti-PD-1 treatments such as nivolumab, 
lambrolizumab, pidilizumab, BMS-93659 (MDX-1105), RG7446/MPDL3280, and MEDI4736 (B7-
H1) has been tested in different cancers including ovarian, colorectal, bladder, and non-small 
cell lung cancer and melanoma. Even though responses vary in different tumor types, anti-
PD-1 treatments are supported. Responses not only vary in different tumor types; some patients 
show clear responses to blockade of PD-1/PD-L1 pathway, whereas they do not respond [4]. 
Currently, it is difficult to predict treatment responses to anti-PD-1 treatments. Expression of 
PD-L1 is not an optimal biomarker, because determination of PD-L1 expression by immunohis-
tochemistry is not always proper due to the different antibody selection and cutoff levels. The 
PD-L1 expression may not anticipate the therapeutic responses because the PD-1/PD-L1 interac-
tions on B cells have role on adaptive and innate immune systems. Nowadays, researchers are 
focused on the potential impact of single nucleotide polymorphisms as predictive therapeutic 
markers and their improvement capacity of the expression markers [20]. In literature, there are 
some studies about the effect of PD-1/PD-L1 SNPs on non-small-cell lung cancer (NSCLC) treat-
ment [20–22]. Nomizo et al. evaluated the association between PD-1/PD-L1 SNPs and response 
to nivolumab, PD-1 immune checkpoint inhibitor, and survival in NSCLC. Five SNPs in PD-L1 
(rs1411262, c.394 + 1999C > A; rs2282055; c.-14–368 > G; rs4143815; c.*395G > C; rs2890658;c.683-
369C > A; rs822339, c.-15 + 2576A > G) and two SNPs in PD-1 (rs2227981; c.804 T > C; rs2227982, 
c.644C > T) were investigated by using real-time polymerase chain reaction (RT-PCR). The G 
allele of rs2282055 and the C allele of rs4143815 in PD-L1 were significantly associated with bet-
ter clinical response than T or G allele, respectively [20]. In a study conducted by Do et al., SNPs 
involved in immune checkpoints were used to predict the clinical outcomes of patients with 
advanced-stage NSCLC after paclitaxel-cisplatin chemotherapy. The SNP rs2297136, c.*93G > A 
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in PD-L1 gene, was significantly associated with better chemotherapy response and better 
overall survival, and rs4143815 in PD-L1 was also found as associated with better response 
to paclitaxel-cisplatin chemotherapy [21]. PD-L1 polymorphisms, especially rs4143815, may be 
promising markers for the prediction of clinical outcome of chemotherapy. However further 
studies with larger patient groups are needed to validate the results from different research 
groups, and also more studies should be designed to figure out PD-L1 in chemotherapy 
responses of different cancers.
2.2. CTLA4 polymorphisms
After the determination and characterization of cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) as a key negative regulator in immune response (broadly named as checkpoint mol-
ecule), studies have increased to develop cancer immunotherapy targeting this co-inhibitory 
molecule. CTLA-4 (CD152) is a member of immunoglobulin (Ig) superfamily and functions 
for downregulation of T-cell activation. CTLA-4 expressed by activated T cells binds to B7.1 
(CD80) and B7.2 (CD86) on antigen-presenting cells and transmits an inhibitory signal to T 
cells, so it can restrict the density and extent of the immune responses. The complex formed 
from CTLA-4 and B7 proteins (B7.1 and B7.2) can switch activated T cells into inhibitory T 
cells. This change promotes tumor escape from immunosurveillance [23]. Although lymphop-
roliferative disorders and severe autoimmune diseases have been shown in CTLA4-knockout 
mice; CTLA-4 blockade can boost immune responses in tumor-transplanted mice, as well as 
extending antitumor immune responses and rejection of tumors [24, 25]. It has been shown 
that blocking of CTLA-4, namely, downregulation of T-cell activation, can lead the cancer 
regression in patients with different cancers due to the enhancing immune responses as well as 
antitumor activity [23, 26]. However, not all patients can benefit from the treatment of CTLA-4 
blockade, and some of them developed severe autoimmune reactions. The mechanisms of this 
interindividual variability in response to immunotherapy are not well understood.
Some CTLA-4 polymorphisms have been investigated with the determination of genetic fac-
tors that may change the response and toxicity of CTLA-4 antibody therapy [27]. Human 
CTLA-4 gene with four exons is located on chromosome 2q33, and different functional sub-
units of CTLA-4 protein such as a leader sequence, an extracellular, a transmembrane, and a 
cytoplasmic domain are encoding [28]. Many SNPs have been identified in the CTLA-4 gene 
that contains three exons and two introns. To date, at least five SNPs that were well studied 
in immune diseases have been investigated in cancer association studies. Among them, the 
rs5742909, c. − 318C > T located in the promoter region; rs231775, c.49A > G located in exon 
1; and rs3087243, c.6230A > G (CT60) located in 3′-untranslated region (3′UTR) have attracted 
more attention. There are more than 100 SNPs in CTLA-4 gene, and most of them are spotted on 
three exons and two introns of CTLA-4 gene. Until now, at least five attracted SNPs have been 
associated in cancer-related studies, such as rs11571316, c. − 1577G > A in the 5′-untranslated 
region (5′UTR); rs5742909, c. − 318C > T in the promoter region; rs231775, c.49A > G in exon 1; 
and rs3087243, c.6230A > G (CT60) in 3′-untranslated region (3′UTR). These alterations change 
the expression or functional activity of CTLA-4 protein [29]. Some common SNPs have been 
reported that they alter either expression or function of the CTLA-4 gene product, as well as 
responses to immunotherapy with anti-CTLA-4 antibodies. A study conducted in melanoma 
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by Breunis et al. has shown that G allele of rs4553808, c.-1660A > G; T allele of rs11571317, c. 
−657C > T; and A allele rs231775, c.49A > G, are significantly associated with response to anti-
CTLA-4 antibody (MDX-010). SNPs rs4553808 and rs11571317 are spotted on the promoter 
region; and rs231775 is on the exon 1 and causes p.Thr17Ala substitution [27]. In another study 
performed by Queirolo P. et al. in metastatic melanoma patients, rs11571316, c. − 1577G > A in 
the 5′UTR, and rs3087243, c.6230A > G (CT60) in the 3′UTR of the gene, were associated with 
best overall response to ipilimumab which is a CTLA-4 immune checkpoint blocker [30]. In 
lung cancer-based study, which is performed by Song B et al., patients with the A allele had a 
significantly shorter survival time than those with the G allele (p value <0.001; survival times: 
AA genotype 9.8 months, GA genotype 12.0 months, GG genotype 12.5 months) [31]. With the 
presented studies above, it can be said that several SNPs in CTLA-4 are biologically functional 
and might be predictive factors for CTLA-4 antibody therapy used for cancers.
2.3. CCR5 polymorphisms
Pro-inflammatory cytokines, chemokines and other protein-structured molecules are secret-
ing from cancerous cells and their stromal environment. Chemokine family belongs to che-
motactic cytokines and has 44 members. Chemokines have role in homeostasis and immunity 
by controlling the leukocyte trafficking and induction, so they have role in organogenesis, cell 
growth, and differentiation. Tumor-related chemokines have important role in cancer biol-
ogy, in terms of leukocyte infiltration, angiogenesis, and immune evasion. Based on the num-
ber and spacing of conserved cysteine residues on their N-terminus, chemokines consist of 
four subgroups named as CX3C, CXC, CC, and C [32, 33]. Chemokines act through their inter-
actions with specific chemokine receptors located on the cell surface. Most of the cancerous 
cells overexpress these specific chemokine receptors which have role together with chemo-
kines in cellular survival, proliferation, migration, invasion, and metastasis. In humans, the 
chemokine receptor family includes 24 members, and they are divided into four subfamilies 
(CX3CR, CXCR, CCR, and CR) based on the class of chemokines that they interact. Specific 
ligand-receptor binding induces GDP to GTP exchange, and this activates the downstream 
signaling effectors for the propagation of cellular pathways [34, 35].
It is considered that chemokine receptors are promising targets for new immunotherapies 
since the detection of overexpressed chemokine receptors on the surface of cancer cells [36]. 
Systemic administration of interleukin-2 and checkpoint inhibitors increases the secretion of 
chemoattractants such as ligands of CCR5 and CXCR. Therefore polymorphisms on CCR5 and 
CXCR chemokine receptors affect the migration capability of tumor-infiltrating lymphocytes 
to the tumor location [37]. So response rates to immunotherapy vary among patients. Ugural 
et al. showed that genotypic status of CCR5 chemokine receptor has an impact on the immu-
notherapy (interferons or interleukin-2) responses in patients with metastatic melanoma. 
A strong association was determined between the CCR5∆32 genotype and overall survival 
as poor prognostic factor. CCR5∆32 polymorphism (rs333, c.554-585del32) consists of 32 bp 
deletion. Heterozygosity causes decreased levels of receptor expression, and homozygosity 
causes the absence of expression. Immunotherapy outcome was worse in metastatic mela-
noma patients who had CCR5∆32 genotype as homozygotes or heterozygotes [38]. Above 
observation of Ugurel et al. clashes with findings of study performed by Bedognetti et al. 
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The presence of CCR5∆32 polymorphism was not correlated with worse response in meta-
static melanoma patients undergoing adoptive therapy [39]. Conflicting studies exist on the 
effect of CCR5∆32 polymorphism on immunotherapy or immunochemotherapy. Hamid et al. 
did not report any significant relationship between the existence of CCR5∆32 genotype or 
rs1799987, c.-301 + 246A > G, polymorphism and responsiveness to ipilimumab [40].
2.4. KIR, HLA, and Fcγ polymorphisms
Natural killer (NK) cells, large granular lymphocytes, have role on the early innate immune 
response. In contrast to T cells, which remember foreign antigens through T-cell receptors in 
the context of major histocompatibility complex (MHC) molecules, NK cells are programmed to 
eliminate infected or transformed cells. Activation of NK cells, known as “missing-self” model 
due to the absence of MHC molecules depends on the numerous signals through their respective 
activating or inhibitory receptors [41]. The killer immunoglobulin-like receptor (KIR) gene encodes 
both activating and inhibitory NK-cell surface receptors. HLA class I gene encodes ligands of 
inhibitory KIR (HLA-C1 for KIR2DL2/3, HLA-C2 for KIR2DL1, HLABw4 for KIR3DL1), and 
the interaction between KIR and HLA class I ligands leads to NK inhibition. NK cells also 
express Fc receptors [42]. The interplay between KIR and HLA is crucial for positive outcomes 
of immune-related therapies. KIR/KIR-ligand mismatch is associated with improved outcome 
to immune-related therapies as well as autologous stem cell transplantation [42].
Delgado et al. reported that KIR receptor-ligand mismatch was related with response or 
improvement of relapsed or refractory neuroblastoma patients receiving interleukin-2-based 
treatment, consistent with a role for NK cells in this clinical response [43].
There are three fragment c gamma receptor (FcγR) classes such as (i) FcgRI, capable of high-
affinity binding monomeric IgG, (ii) FcgRII with low-affinity binding, and (iii) FcgRIII inter-
action with complexed IgG. FcgRII and FcgRIII have variants with different binding affinity 
immune complexes such as FcgRIIa (131H/R) and FcgRIIIa (Val158Phe) [44].
Several groups have investigated the role of FcγR polymorphisms in the response of mono-
clonal antibodies (mAbs) such as rituximab, cetuximab, and trastuzumab. A correlation 
was reported between FcgRIIa polymorphisms and complete response in rituximab-based 
regimen received by non-Hodgkin lymphoma patients [44]. In another study performed to 
understand the influence of the FCGR3A gene polymorphism on rituximab response of non-
Hodgkin lymphoma patients, again a correlation was found between FCGR3A genotype and 
clinical response [45]. In a preliminary study, FCGR2A and FCGR3A polymorphisms were 
shown as useful markers to predict clinical outcome in metastatic colorectal cancer patients 
treated with cetuximab, a chimeric immunoglobulin G1 (IgG1) monoclonal antibody (mAb) 
against epidermal growth factor receptor (EGFR) [46]. Musolino et al. reported a correlation 
between FCGR3A and objective response rate and progression-free survival in patients with 
HER-2/neu-amplified breast cancer receiving trastuzumab. Also an association was deter-
mined between the combination of FCGR2A and FCGR3A and better objective response rate 
and progression-free survival [47]. Cheung et al. reported an association between FcγR2A 
polymorphism and progression-free survival in the response of neuroblastoma patients to the 
anti-GD2 antibody [48]. As a result, KIR-HLA immunogenetics can give useful information 
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about the activation of innate immunity, and combining KIR-HLA genotyping with other 
molecular markers such as Fcγ receptor polymorphisms that can give insight about immune 
responsiveness may allow clinicians to determine the most effective and least toxic personal-
ized immunotherapy.
3. Conclusion and future aspects
Immunogenomics uses advance genomic analysis tools to distinguish the limitations of the 
immune system, and pharmacogenomics identifies the variability of pharmacologic responses 
based on individual’s genetic/germline variations. Integration of both immunogenomics and 
pharmacogenomics forms immunopharmacogenomics to revolutionize the immunotherapy 
applications through the identification of genetic status of immunoregulatory molecules. This 
approach could be used to develop a better understanding for immunologic reactions, select 
patients for immunotherapy, and predict the side effects and response to anticancer treatment 
(not only immunotherapy but also chemo/radiation therapy). Although the immunopharma-
cogenetic applications are limited in clinical practice, it is clear that immunopharmacogenom-
ics will become an important approach of cancer management in immunotherapy era.
Conflict of interest
Authors declare no conflict of interest.
Author details
Gizem Calibasi-Kocal1 and Yasemin Baskin2,3*
*Address all correspondence to: yasemin.baskin@deu.edu.tr
1 Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, 
Turkey
2 Department of Biostatistics and Medical Informatics, Faculty of Medicine, Dokuz Eylul 
University, Izmir, Turkey
3 Personalized Medicine and Pharmacogenomics Research Center, Dokuz Eylul University, 
Izmir, Turkey
References
[1] Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the 
end of cancer? BMC Medicine. 2016;14:73. DOI: 10.1186/s12916-016-0623-5
Immunopharmacogenomics in Cancer Management
http://dx.doi.org/10.5772/intechopen.76934
149
[2] Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164(6):1233-1247. 
DOI: 10.1016/j.cell.2016.01.049
[3] Snyder MW, Adey A, Kitzman JO, Shendure J. Haplotype-resolved genome sequencing: 
Experimental methods and applications. Nature Reviews. Genetics. 2015;16(6):344-358. 
DOI: 10.1038/nrg3903
[4] Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, Zal M, 
Nesaei A, Hosseini SM. PD-1 and cancer: Molecular mechanisms and polymorphisms. 
Immunogenetics. 2018;70(2):73-86. DOI: 10.1007/s00251-017-1015-5
[5] Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy 
beyond immune checkpoint inhibitors. Journal of Hematology & Oncology. 2018;11(1):8. 
DOI: 10.1186/s13045-017-0552-6
[6] Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have we found the 
key to unleash the antitumor immune response? Frontiers in Immunology. 2017;8:1597. 
DOI: 10.3389/fimmu.2017.01597
[7] Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 
pathway in immunological tolerance and autoimmunity. Autoimmunity Reviews. 
2013;12(11):1091-1100. DOI: 10.1016/j.autrev.2013.05.003
[8] Cheng S, Zheng J, Zhu J, Xie C, Zhang X, Han X, Song B, Ma Y, Liu J. PD-L1 gene polymor-
phism and high level of plasma soluble PD-L1 protein may be associated with non-small 
cell lung cancer. The International Journal of Biological Markers. 2015;30(4):e364-e368. 
DOI: 10.5301/jbm.5000170
[9] Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, Kim KH. Association of PD-L1 expres-
sion and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma 
and squamous cell carcinoma. Human Pathology. 2017;68:103-111. DOI: 10.1016/j.
humpath.2017.08.016
[10] Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst 
RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-
small cell lung cancer. Laboratory Investigation. 2014;94(1):107-116. DOI: 10.1038/
labinvest.2013.130
[11] Sasaki H, Tatemaysu T, Okuda K, Moriyama S, Yano M, Fujii Y. PD-1 gene promoter 
polymorphisms correlate with a poor prognosis in non-small cell lung cancer. Molecular 
and Clinical Oncology. 2014;2(6):1035-1042. DOI: 10.3892/mco.2014.358
[12] Hua Z, Li D, Xiang G, Xu F, Jie G, Fu Z, Jie Z, Da P, Li D. PD-1 polymorphisms are associ-
ated with sporadic breast cancer in Chinese Han population of Northeast China. Breast 
Cancer Research and Treatment. 2011;129(1):195-201. DOI: 10.1007/s10549-011-1440-3
[13] Yousefi AR, Karimi MH, Shamsdin SA, Mehrabani D, Hosseini SV, Erfani N, Bolandparvaz 
S, Bagheri K. PD-1 gene polymorphisms in Iranian patients with colorectal cancer. Lab 
Medicine. 2013;44:241-244. DOI: 10.1309/LMG1BS4J3TAONRQF
Genetic Diversity and Disease Susceptibility150
[14] Haghshenas MR, Dabbaghmanesh MH, Miri A, Ghaderi A, Erfani N. Association of 
PDCD1 gene markers with susceptibility to thyroid cancer. Journal of Endocrinological 
Investigation. 2017;40(5):481-486. DOI: 10.1007/s40618-016-0579-5
[15] Haghshenas MR, Naeimi S, Talei A, Ghaderi A, Erfani N. Program death 1 (PD1) haplotyp-
ing in patients with breast carcinoma. Molecular Biology Reports. 2011;38(6):4205-4210. 
DOI: 10.1007/s11033-010-0542-z
[16] Yin L, Guo H, Zhao L, Wang J. The programmed death-1 gene polymorphism (PD-1.5 
C/T) is associated with non-small cell lung cancer risk in a Chinese Han population. 
International Journal of Clinical and Experimental Medicine. 2014;7(12):5832-5836
[17] Zhou RM, Li Y, Wang N, Huang X, Cao SR, Shan BE. Association of programmed death-1 
polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma. 
Cancer Genetics. 2016;209(9):365-375. DOI: 10.1016/j.cancergen.2016.06.006
[18] Zhou RM, Li Y, Liu JH, Wang N, Huang X, Cao SR, Shan BE. Programmed death-1 
ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squa-
mous cell carcinoma in smokers. Cancer Biomarkers. 2017;21(1):65-71. DOI: 10.3233/
CBM-170269
[19] Tao LH, Zhou XR, Li FC, Chen Q, Meng FY, Mao Y, Li R, Hua D, Zhang HJ, Wang 
WP, Chen WC. A polymorphism in the promoter region of PD-L1 serves as a binding-
site for SP1 and is associated with PD-L1 overexpression and increased occurrence of 
gastric cancer. Cancer Immunology, Immunotherapy. 2017;66(3):309-318. DOI: 10.1007/
s00262-016-1936-0
[20] Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai 
H, Hirai T, Kim YH. Clinical impact of single nucleotide polymorphism in PD-L1 on 
response to nivolumab for advanced non-small-cell lung cancer patients. Scientific 
Reports. 2017;7:45124. DOI: 10.1038/srep45124
[21] Do SK, Lee SY, Choi JE, Hong MJ, Lee JH, Park JY. PD-L1 polymorphism can predict 
clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-
cisplatin chemotherapy. Journal of Thoracic Oncology. 2016;11(4 Suppl):S125. DOI: 
10.1038/srep25952
[22] Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, Do SK, Kang HG, Lee WK, Seok Y, Lee EB, 
Jeong JY, Shin KM, Yoo SS, Lee J, Cha SI, Kim CH, Park JY. Functional polymorphisms in 
PD-L1 gene are associated with the prognosis of patients with early stage non-small cell 
lung cancer. Gene. 2017;599:28-35. DOI: 10.1016/j.gene.2016.11.007
[23] Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-
Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman 
A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 
4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carci-
noma patients. Proceedings of the National Academy of Sciences of the United States of 
America. 2003;100(8):4712-4717. DOI: 10.1073/pnas.0830997100
Immunopharmacogenomics in Cancer Management
http://dx.doi.org/10.5772/intechopen.76934
151
[24] Sun T, Hu Z, Shen H, Lin D. Genetic polymorphisms in cytotoxic T-lymphocyte anti-
gen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer 
Research. 2009;69(15):6011-6014. DOI: 10.1158/0008-5472.CAN-09-0176
[25] Ma Y, Liu X, Zhu J, Li W, Guo L, Han X, Song B, Cheng S, Jie L. Polymorphisms of co-
inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer 
in a Chinese population. International Journal of Clinical and Experimental Medicine. 
2015;8(9):16585-16591
[26] Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, 
Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg 
SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced 
by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic 
melanoma. Proceedings of the National Academy of Sciences of the United States of 
America. 2003;100(14):8372-8377. DOI: 10.1073/pnas.1533209100
[27] Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ. Influence 
of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms 
on outcome in treatment of melanoma patients with CTLA-4 blockade. Journal of 
Immunotherapy. 2008;31(6):586-590. DOI: 10.1097/CJI.0b013e31817fd8f3
[28] Qi P, Ruan CP, Wang H, Zhou FG, Xu XY, Gu X, Zhao YP, Dou TH, Gao CF. CTLA-4 
+49A>G polymorphism is associated with the risk but not with the progression of 
colorectal cancer in Chinese. International Journal of Colorectal Disease. 2010;25(1):39-
45. DOI: 10.1007/s00384-009-0806-z
[29] Xiaolei L, Baohong Y, Haipeng R, Shuzhen L, Jianfeng G, Xiangpo P, Haiyu L, Yuan Y, 
Dejie Z, Jinhong Y, Huanxin W, Wenhui W, Guohua Y. Current evidence on the cytotoxic 
T-lymphocyte antigen 4 + 49G > A polymorphism and digestive system cancer risks: 
A meta-analysis involving 11,923 subjects. Meta Gene. 2015;6:105-108. DOI: 10.1016/j.
mgene.2015.09.005
[30] Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent 
S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone 
M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida 
M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, 
Spagnolo F, Pistillo MP. Association of CTLA-4 gene variants with response to therapy 
and long-term survival in metastatic melanoma patients treated with ipilimumab: An 
Italian Melanoma Intergroup Study. Frontiers in Immunology. 2017;8:386. DOI: 10.3389/
fimmu.2017.00386
[31] Song B, Liu Y, Liu J, Song X, Wang Z, Wang M, Zhu Y, Han J. CTLA-4 +49A>G polymor-
phism is associated with advanced non-small cell lung cancer prognosis. Respiration. 
2011;82(5):439-444. DOI: 10.1159/000329345
[32] Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific anti-
bodies in cancer immunotherapy: Achievements and challenges. Frontiers in Immunology. 
2015;6:12. DOI: 10.3389/fimmu.2015.00012
Genetic Diversity and Disease Susceptibility152
[33] Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, 
Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy 
PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, 
Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. 
[corrected]. LXXXIX. Update on the extended family of chemokine receptors and intro-
ducing a new nomenclature for atypical chemokine receptors. Pharmacological Reviews. 
2013;66(1):1-79. DOI: 10.1124/pr.113.007724
[34] Kufareva I, Salanga CL, Handel TM. Chemokine and chemokine receptor structure 
and interactions: implications for therapeutic strategies. Immunology and Cell Biology. 
2015;93(4):372-383. DOI: 10.1038/icb.2015.15
[35] Lazennec G, Richmond A. Chemokines and chemokine receptors: New insights into 
cancer-related inflammation. Trends in Molecular Medicine. 2010;16(3):133-144. DOI: 
10.1016/j.molmed.2010.01.003
[36] Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine 
system in cancer biology and therapy. Cytokine & Growth Factor Reviews. 2010;21(1):27-
39. DOI: 10.1016/j.cytogfr.2009.11.007
[37] Chow MT, Luster AD. Chemokines in cancer. Cancer Immunology Research. 2014;2(12): 
1125-1131. DOI: 10.1158/2326-6066.CIR-14-0160
[38] Ugurel S, Schrama D, Keller G, Schadendorf D, Bröcker EB, Houben R, Zapatka M, 
Fink W, Kaufman HL, Becker JC. Impact of the CCR5 gene polymorphism on the sur-
vival of metastatic melanoma patients receiving immunotherapy. Cancer Immunology, 
Immunotherapy. 2008;57(5):685-691. DOI: 10.1007/s00262-007-0407-z
[39] Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De 
Giorgi V, Liu Q, Delogu LG, Sommariva M, Sertoli MR, Simon R, Wang E, Rosenberg SA, 
Marincola FM. CXCR3/CCR5 pathways in metastatic melanoma patients treated with 
adoptive therapy and interleukin-2. British Journal of Cancer. 2013;109(9):2412-2423. 
DOI: 10.1038/bjc.2013.557
[40] Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, 
Gómez H, Bastholt L, Chasalow SD, Berman D. A prospective phase II trial exploring 
the association between tumor microenvironment biomarkers and clinical activity of 
ipilimumab in advanced melanoma. Journal of Translational Medicine. 2011;9:204. DOI: 
10.1186/1479-5876-9-204
[41] Lanier LL. NK cell recognition. Annual Review of Immunology. 2005;23:225-274. DOI: 
10.1146/annurev.immunol.23.021704.115526
[42] Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, 
Cheung NK, Hsu KC. KIR and HLA genotypes are associated with disease progression 
and survival following autologous hematopoietic stem cell transplantation for high-risk 
neuroblastoma. Clinical Cancer Research. 2009;15(23):7330-7334. DOI: 10.1158/1078-0432. 
CCR-09-1720
Immunopharmacogenomics in Cancer Management
http://dx.doi.org/10.5772/intechopen.76934
153
[43] Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies 
SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, 
Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the 
response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Research. 
2010;70(23):9554-9561. DOI: 10.1158/0008-5472.CAN-10-2211
[44] Paiva M, Marques H, Martins A, Ferreira P, Catarino R, Medeiros R. FcgammaRIIa poly-
morphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer 
Genetics and Cytogenetics. 2008;183(1):35-40. DOI: 10.1016/j.cancergencyto.2008.02.001
[45] Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism 
in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. DOI: 10.1182/blood.
V99.3.754
[46] Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, 
Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. FCGR2A and FCGR3A 
polymorphisms associated with clinical outcome of epidermal growth factor receptor 
expressing metastatic colorectal cancer patients treated with single-agent cetuximab. 
Journal of Clinical Oncology. 2007;25(24):3712-3718. DOI: 10.1200/JCO.2006.08.8021
[47] Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, 
Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Immunoglobulin G fragment 
C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in 
patients with HER-2/neu-positive metastatic breast cancer. Journal of Clinical Oncology. 
2008;26(11):1789-1796. DOI: 10.1200/JCO.2007.14.8957
[48] Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A poly-
morphism is correlated with clinical outcome after immunotherapy of neuroblastoma 
with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. Journal 
of Clinical Oncology. 2006;24(18):2885-2890. DOI: 10.1200/JCO.2005.04.6011
Genetic Diversity and Disease Susceptibility154
